LEXEO Therapeutics
Emily H. began their work experience as an Extern at CipherHealth in 2014 and went on to hold various roles, including Non Profit Development Intern at Dwight Hall, Intern at BlueMax Networks, Business Development Intern at Devil Dog Liquor, and Buttery Manager at Jonathan Edwards Residential College Buttery. Emily then transitioned to the role of Undergraduate Researcher at Yale Department of Biology, Dr. Craig Crews. Emily proceeded to work as a Financial Analyst at Caine Mitter & Associates Inc., and later joined Regeneron Pharmaceuticals, Inc. where they held positions such as Financial Analyst in Program Finance, Sr. Financial Analyst in Corporate Finance, and Sr. Financial Analyst in Program Finance. Emily then moved on to Ovid Therapeutics, where they served as Manager FP&A, Associate Director FP&A, and Associate Director Business Development. Emily is currently the Director of Business Development at LEXEO Therapeutics.
Emily H. attended the University of Arizona as a non-degree seeking undergraduate from 2009 to 2010. Emily then pursued a Bachelor of Science in Molecular, Cellular, and Developmental Biology at Yale University from 2011 to 2015. In addition, they obtained the Series 50 Certified Municipal Advisor Representative certification from the Municipal Securities Rulemaking Board.
This person is not in any teams
LEXEO Therapeutics
LEXEO Therapeutics is a New York City-based, fully integrated biotechnology company currently headquartered at the Alexandria Center® for Life Science that aims to apply the transformational science of gene therapy to address some of the world’s most devastating genetic and acquired diseases. LEXEO Therapeutics’ pipeline consists of adeno-associated virus (AAV)-mediated therapies primarily developed at Weill Cornell Medicine’s Department of Genetic Medicine.